Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NANot yet recruitingINTERVENTIONAL
Enrollment
790
Participants
Timeline
Start Date
August 1, 2025
Primary Completion Date
December 1, 2026
Study Completion Date
January 1, 2027
Conditions
HCC - Hepatocellular Carcinoma
Interventions
DEVICE
Heterogeneous Treatment Effect-Based Decision Model
Heterogeneous Treatment Effect-Based Decision Model
All Listed Sponsors
lead
Zhongda Hospital
OTHER
NCT07109336 - Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter